Brigham Young University Law Review | November 11, 2021Read the Publication
Pharmaceutical patents represent some of the most valuable intellectual property assets for drug companies. These patents can be worth billions of dollars if found valid and infringed. Correspondingly, if invalidated, generic drug manufacturers can get to market earlier, generating billions of dollars of added revenue. Accordingly, drug patents are associated with high-value, high-cost, bet-the-company type prosecution and litigation.